The antiviral activity of the drug Kagocel®, which has a high safety profile and proven efficacy for the prevention and treatment of influenza and AVRI as an interferon inducer, was studied against a new pandemic strain of SARS-CoV-2 in vitro in Vero C1008 cell culture. The results of the study revealed that at the addition of the substance Kagocel® at the concentration of 5000 µg/ml into the cell culture 1 h before the virus infection and 1 h after, there was 100% inhibition of the cytopathic activity of the virus. It was also found that Kagocel® at the dose of 5000 µg/ml effectively suppressed the reproduction of the SARS-CoV-2 virus, variant B, in Vero C1008 cell culture by 1.75 Ig, the inhibition coefficient was 97.83 %.